

API PORTFOLIO

COMMERCIAL SCALE

Sr. No.	Product	USDMF	EDMF	CEP	JDMF	KDMF	DMF	Therapeutic Category
1	Acitretin	✓	✓	✓*			✓	Treatment of Psoriasis
2	Barnidipine HCl		✓#					Antihypertensive
3	Bicalutamide		✓		✓		✓	Treatment of Prostate Cancer
4	Blended Metformin (0.5% Mag. Stearate)	✓						Antidiabetic
5	Clopidogrel Hydrogen Sulphate		✓	✓				Antiplatelet
6	Dabigatran Etxilate Mesylate			✓*				Anticoagulant
7	Dapagliflozin	✓*	✓*					Antidiabetic
8	Dolasetron Mesylate	✓						Nausea & Vomiting (chemo induced)
9	Donepezil HCl Monohydrate (Form-I)	✓	✓	✓		✓		Dementia
10	Edoxaban Tosylate Monohydrate		✓#					Cardiovascular
11	Elagolix Sodium	✓#						GnRH Antagonist
12	Empagliflozin	✓*	✓#					Antidiabetic
13	Etelcalcetide HCl ^Δ	✓						Antidiabetic
14	Glimepiride	✓		✓	✓	✓	✓	Antidiabetic
15	Glipizide	✓	✓					Antidiabetic
16	Glyburide / Glibenclamide	✓		✓			✓	Antidiabetic
17	Icatibant Acetate	✓	✓				✓	Immunomodulators
18	Imiquimod	✓					✓	Immune Response Modifiers
19	Liraglutide	✓#	✓#					Antidiabetic
20	Metformin HCl DC Granules 86.66% & 95% w/w	✓	✓				✓	Antidiabetic
21	Metformin HCl with (0.5%/ 1%/ 5% Silicon Dioxide)		✓					Antidiabetic
22	Metformin HCl	✓		✓	✓	✓	✓	Antidiabetic
23	Naratriptan HCl	✓	✓		✓	✓	✓	Pain Management
24	Nateglinide	✓					✓	Antidiabetic
25	Octreotide Acetate	✓					✓	Treatment of Severe Diarrhea
26	Olopatadine HCl	✓	✓				✓	Antihistamine
27	Palonoseteron HCl	✓	✓				✓	Nausea & Vomiting (chemo induced)
28	Pioglitazone HCl	✓	✓			✓		Antidiabetic
29	Regadenoson ^Δ	✓						Pharmacologic Stress Testing
30	Repaglinide	✓		✓			✓	Antidiabetic
31	Rivaroxaban ^Δ			✓				Anticoagulant
32	Ropinirole HCl	✓	✓				✓	Treatment of Parkinsons Disease
33	Sugammadex Sodium	✓	✓		✓	✓	✓	Neuromuscular reversal
34	Ticagrelor ^Δ	✓	✓	✓			✓	Cardiovascular
35	Trimetazidine Di-HCl	✓		✓		✓	✓	Cardiovascular
36	Zoledronic Acid ^Δ	✓	✓	✓		✓	✓	Treatment of Hypercalcemia

* products under review

products to be filed

Δ products available only for non-US markets

Please reach out to international@usv.in for any API related enquiries

Disclaimer: USV does not offer any product which is under patent protection for commercial use/sale. Such product shall be available solely for R&D/regulatory use in accordance with the applicable patent laws and/or any such relevant law or safe harbor provision, of the respective countries, regions or jurisdictions.

UNDER DEVELOPMENT

Sr. No.	Product	Therapeutic Category
1	Apixaban	Cardiovascular
2	Apremilast	Immunosuppressants/Psoriasis and Psoriatic Arthritis
3	Macitentan	CVS/Pulmonary Arterial Hypertension
4	Sacubitril - Valsartan Co-crystal	Cardiovascular
5	Semaglutide	Antidiabetic

NEW PIPELINE PRODUCTS

Sr. No.	Product	Therapeutic Category
1	Abrocitinib	Dermatologicals/Atopic Dermatitis
2	Atogepant	To prevent migraines
3	Fezolinetant	Treatment of Vasomotor Symptoms
4	Finerenone	CVS/Heart failure with CKD in type II diabetes patients
4	Mirabegron	Urological/Overactive Bladder
6	Resmetirom	Treatment of Non-Alcoholic Fatty Liver
7	Tirzepatide	Antidiabetic

Please reach out to international@usv.in for any API related enquiries

FDF PORTFOLIO

READY DOSSIER

Sr. No.	Product	Strength	Therapeutic Category
1	Acitretin Capsules	10mg, 25mg	Dermatology
2	Apixaban Tablets	2.5mg, 5mg	Anticoagulant
3	Chlorthalidone Tablets	25mg, 50mg	Diuretic
4	Clopidogrel Tablets	75mg	Antiplatelet Agent
5	Colesevelam Tablets	625mg	CVS- Lipid lowering agent
6	Dapagliflozin + Metformin IR Tablets	5mg+850mg, 5mg+1000mg	Antidiabetic
7	Donepezil Tablets	5mg, 10mg	Alzheimer's Disease
8	Dapagliflozin Tablets	5mg, 10mg	Antidiabetic
9	Etelcalcetide Injection*	2.5mg/0.5ml, 5mg/1ml, 10mg/2ml vial	Antiparathyroid Agent
10	Etoricoxib Tablets	30mg, 60mg, 90mg, 120mg	NSAID
11	Felodipine ER Tablets	2.5mg, 5mg, 10mg	CVS- Calcium Channel Blocker
12	Glycopyrrolate Injection	0.2mg/1ml, 0.4mg/2ml- Single dose vial 1mg/5ml, 4mg/20ml- Multidose vial	Anticholinergic Agent
13	Glycopyrrolate Tablets	1mg, 2mg	Anticholinergic Agent
14	Icatibant Acetate Injection	30mg/3ml PFS	Hereditary Angioedema
15	Irbesartan Tablets	150mg, 300mg	CVS-Angiotensin Receptor Blocker
16	Metformin + Vildagliptin Tablets	850mg+50mg, 1000mg+50mg	Antidiabetic
17	Metformin + Glibenclamide Tablets	500mg+5mg, 2.5+500mg, 1.25+250mg	Antidiabetic
18	Metformin + Glimepiride Tablets	500mg+2mg	Antidiabetic
19	Metformin IR Tablets	500mg, 850mg, 1000mg	Antidiabetic
20	Metformin ER Tablets	500mg, 1000mg (Glumetza)	Antidiabetic
21	Metformin ER Tablets	500, 750mg, 1000mg (Glucophage XR)	Antidiabetic
22	Naratriptan Tablets	1mg, 2.5mg	Antimigraine
23	Octreotide Injection (Short acting)	50mcg/1ml, 100mcg/1ml, 500mcg/1ml- Single dose vial 1mg/5ml, 5mg/5ml- Multidose 5ml vial	Growth Hormone Inhibitor
24	Olopatadine Ophthalmic solution	0.1% - 5ml Bottle	Antihistaminic
25	Olopatadine Ophthalmic solution	0.2% - 2.5ml Bottle	Antihistaminic
26	Palonosetron Injection	0.25mg/5ml vial	Antiemetic
27	Peg. Filgrastim Injection	6mg/0.6ml PFS	Immunomodulator
28	Ranolazine PR Tablets	375mg, 500mg, 750mg	CVS-Chronic Angina
29	Regadenoson Injection*	0.40mg/5ml PFS	Pharmacological Stress Agent
30	Rivaroxaban Tablets*	2.5mg, 10mg, 15mg, 20mg	Anticoagulant
31	Rosuvastatin Tablets	5mg, 10mg, 20mg, 40mg	CVS-Lipid Lowering Agent
32	Sugammadex Injection	200mg/2ml, 500mg/5ml vial	Reversal of Neuro Muscular Blockade (Anesthesia)
33	Ticagrelor Tablets*	60mg, 90mg	Antiplatelet Agent
34	Zoledronic Acid Injection*	4mg/5ml vial	Bone Disease

Please reach out to international@usv.in for any FDF related enquiries

DISCLAIMER : USV does not offer any product which is under patent protection for commercial use/sale. Such product shall be available solely for R&D/regulatory use in accordance with the applicable patent laws and/or any such relevant law or safe harbor provision, of the respective countries, regions or jurisdictions.

*Dossier availability for US market will be subject to the terms & conditions

UNDER DEVELOPMENT

Sr. No.	Product	Strength	Therapeutic Category	Dossier readiness
1	Apremilast Tablets	10mg, 20mg, 30mg	Immunomodulator	Q3-2025
2	Dapagliflozin+Metformin XR Tablets	2.5mg+1gm, 5mg+500mg, 5mg+1gm, 10mg+500mg, 10mg+1gm	Antidiabetic	Q4-2025
3	Empagliflozin Tablets	10mg, 25mg	Antidiabetic	Q1-2025
4	Empagliflozin+Metformin IR Tablets	5mg+500mg, 5mg+850mg, 5mg+1gm, 12.5mg+500mg, 12.5mg+850mg, 12.5mg+1gm	Antidiabetic	Q2-2025
5	Empagliflozin+Metformin XR Tablets	5mg+1gm, 10mg+1gm, 12.5mg+1gm, 25mg+1gm	Antidiabetic	Q1-2026
6	Edoxaban Tablets	15mg, 30mg, 60mg	Anticoagulant	Q4-2025
7	Elagolix Tablets	150mg, 200mg	Pain associated with endometriosis	Q4-2025
8	Galantamine ER Capsules	8mg, 16mg, 24mg	Alzheimer's disease	Under development
9	Macitentan Tablets	10mg	CVS-Pulmonary arterial hypertension	Q3-2025
10	Mesalamine DR Tablets	1.2gm	Anti Inflammatory	Q2-2025
11	Mirabegron ER Tablets	25mg, 50mg	Overactive bladder	Q4-2025
12	Liraglutide Injection	18mg/3ml -Cartridge in 3-Dose Pen Device	Antidiabetic	Q3-2025
13	Liraglutide Injection	18mg/3ml -Cartridge in 5-Dose Pen Device	Anti Obesity	Q3-2025
14	Semaglutide Injection	2mg/3ml, 4mg/3ml & 8mg/3ml Pen Device	Antidiabetic	Q3-2025
15	Semaglutide Tablets	3mg, 7mg, 14mg	Antidiabetic	Under development
16	Sacubitril+Valsartan Tablets	24mg+26mg, 49mg+51mg, 97mg+103mg	CVS-Chronic heart failure	Q4-2026
17	Tirzepatide Injection	2.5 mg/0.5ml, 5 mg/0.5ml, 7.5 mg/0.5ml, 10 mg/0.5ml, 12.5 mg/0.5ml, 15 mg/0.5ml	Antidiabetic	Q4-2026

ONCOLOGY

Sr. No.	Product	Strength	Therapeutic Category	Dossier readiness
1	Cabozantinib Tablets	20mg, 40mg, 60mg	Renal, Hepatocellular, Thyroid carcinoma	Early development
2	Dasatinib Tablets	20mg, 50mg, 70mg, 80mg, 100mg, 140mg	Blood Cancer	Q3-2024
3	Ibrutinib Tablets	140mg, 280mg, 420mg, 560mg	Blood Cancer	Q3-2025
4	Lenvatinib Capules	4mg, 10 mg	Thyroid, Renal cell, Endometrial	Early development
5	Olaparib Tablets	100mg, 150mg	Ovarian Cancer	Q3-2026
6	Osimertinib Tablets	40mg, 80mg	Lung cancer	Early development
7	Palbociclib Tablets	75mg, 100mg, 125mg	Breast Cancer	Q1-2025
8	Pomalidomide Capsules	1mg, 2mg, 3mg, 4mg	Blood Cancer	Q4-2024
9	Ruxolitinib Tablets	5mg, 10mg, 15mg, 20mg, 25mg	Blood Cancer	Q2-2025
10	Venetoclax Tablets	10mg, 50mg, 100mg	Blood Cancer	Early development

Please reach out to international@usv.in for any FDF related enquiries

DISCLAIMER : USV does not offer any product which is under patent protection for commercial use/sale. Such product shall be available solely for R&D/regulatory use in accordance with the applicable patent laws and/or any such relevant law or safe harbor provision, of the respective countries, regions or jurisdictions.

*Dossier availability for US market will be subject to the terms & conditions